This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Onyx Holder's Winning Angle

Timing is everything on Wall Street. Take Onyx Pharmaceuticals' (ONXX) dealings with an offshore hedge fund.

Shares of the California biotech got shellacked Monday, falling 30% on news that kidney cancer drug Nexavar didn't work in some patients. The one-day plunge wiped out $223 million in market cap for the money-losing biotech, which has a partnership with Germany's Bayer (BAY).

Onyx's bad clinical results caused a lot of pain for shareholders. But the company isn't feeling quite so bad. After all, the Nexavar news came just weeks after Onyx sold a big block of stock to hedge fund Azimuth Opportunity.

A Nov. 17 filing indicates that Onyx planned to raise $40 million by selling 2.2 million shares to Azimuth at an average price of $17.94. The deal, which came under a larger agreement between Onyx and Azimuth, gave Azimuth a 2% discount to the then-prevailing market price.

With Onyx shares having plunged Monday to close at $12.18, Azimuth appears to be severely underwater on the trade. But Wall Streeters say don't fret for the British Virgin Islands-based fund.

Observers say it's likely the hedge fund quickly unloaded at least some of the discounted shares -- as is common in a PIPE, or private investment in public equity, deal. There's no precise way to track whether the shares were sold, but filings show Azimuth wasn't restricted. "Any sale of our shares of common stock to Azimuth will be registered on our registration statement," an Onyx filing states -- meaning shares can be promptly resold.

Indeed, trading volume in shares of Onyx was heavier than normal in six of the nine days since the deal's scheduled Nov. 20 close, leading up to Monday's debacle. Azimuth couldn't be reached for comment.

The investors who may have gotten hurt the most in Monday's fierce selloff were the ones buying any shares Azimuth may have sold. Officials with Onyx didn't return telephone calls. An attorney for the company declined to comment.

The sale of stock to Azimuth was part of a special kind of PIPE deal known as a stock-equity line. In a stock-equity line, a company strikes a deal to sell discounted shares to a hedge fund from time to time. The arrangement is similar to a secondary, or a follow-on, offering of shares, in that the sales are done at the discretion of the company.

In its deal with Azimuth, agreed to in September, Onyx stands to raise $150 million over two years from the periodic stock sales.

The November stock sale was the second one under the stock-equity line. In October, Onyx sold 2.1 million shares to Azimuth in a deal that netted $34.6 million for the company. The shares in that transaction were sold at a 3% to 5% discount to the then market price of $17.29.

Shares of Onyx rallied in the days after that stock sale, closing as high as $19.60 on Nov. 8.

Azimuth, meanwhile, is making a cottage industry out of stock-equity lines. The deal with Onyx is the 11th such financing transaction it has agreed to this year. Other companies it has reached similar deals with include Solexa (SLXA), Nanogen (NGEN) and Encysive (ENCY), according to PlacementTracker.

As is the case with most PIPEs, the companies doing stock-equity-line deals tend to be small-cap companies in need of cash. The arrangement is good for companies because it enables them to obtain a ready supply of capital.

But critics contend stock-equity lines dilute the value of existing shares by pumping more stock into the market. They say these deals, regardless of their cash-raising potential, are bad for investors.

Onyx shareholders might be inclined to agree about now.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,106.70 +29.83 0.17%
S&P 500 2,000.02 +2.10 0.11%
NASDAQ 4,570.6370 +13.29 0.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs